申请人:ESBATECH AG
公开号:WO2005120513A1
公开(公告)日:2005-12-22
The present invention relates to the use of compounds for the treatment of disorders involving a protein kinase, preferably a tyrosine kinase. The compounds e.g. have the general formula (I) wherein R1, R2 and R4 are independently selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 cycloalkyl, NR6R7, OR6, SR6, (CH)mR6R7, wherein R6 and R7 are independently selected from hydrogen, optionally substituted C3-C8 cycloalkyl, optionally substituted aryl, optionally substituted 5- or 6- membered heterocycle, (CH2)nCO(O)R8, (CH2)mR' where n = 0, 1, 2, 3, 4 and wherein R8 is hydrogen, C1-C6 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted aryl and wherein R' is selected from hydrogen, C1-C6 alkyl, C1-C6 alkoxy, optionally substituted aryl, halogen, hydroxyl, NO2, NH2, SO2NH2, cyano and m is 0, 1, 2, 3, 4; R3 is hydroxyl, halogen, NH2, NO2, cyano, SH, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted aryl, optionally substituted 5- or 6-membered heterocycle, R5 is selected from C1-C6 alkyl, hydrogen, alkoxy, NH2, halogen, cyano, alkine, COOR'' wherein R'' is selected from hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl.
本发明涉及化合物在治疗涉及蛋白激酶,优选为酪氨酸激酶的紊乱症状中的用途。这些化合物具有一般式(I),其中R1、R2和R4分别选择自氢、可选地取代的C1-C6烷基、可选地取代的C3-C8环烷基、NR6R7、OR6、SR6、(CH)mR6R7,其中R6和R7分别选择自氢、可选地取代的C3-C8环烷基、可选地取代的芳基、可选地取代的5-或6-成员杂环、(CH2)nCO(O)R8、(CH2)mR',其中n = 0, 1, 2, 3, 4,其中R8为氢、C1-C6烷基、可选地取代的C3-C8环烷基、可选地取代的芳基,R'选择自氢、C1-C6烷基、C1-C6烷氧基、可选地取代的芳基、卤素、羟基、NO2、NH2、SO2NH2、氰基,m为0, 1, 2, 3, 4;R3为羟基、卤素、NH2、NO2、氰基、巯基、可选地取代的C1-C6烷基、可选地取代的C3-C8环烷基、可选地取代的芳基、可选地取代的5-或6-成员杂环,R5选择自C1-C6烷基、氢、烷氧基、NH2、卤素、氰基、炔烃、COOR'',其中R''选择自氢、C1-C6烷基、C3-C8环烷基。